Navigation Links
Tengion Provides Business Update and Reports Second Quarter 2011 Financial Results
Date:8/9/2011

, the Company held $25.2 million in cash, cash equivalents, and short-term investments.  

Conference Call and WebcastDavid I. Scheer, Chairman of the Board of Directors, and A. Brian Davis, Chief Financial Officer and Vice President of Finance, will host a conference call today, August 9, 2011 at 5:00 p.m. ET to provide a business update and discuss the Company's second quarter 2011 financial results.  Tim Bertram, D.V.M., Ph.D., Executive Vice President, Science & Technology and Chief Scientific Officer and Sunita Sheth, M.D., Chief Medical Officer and Vice President Clinical and Regulatory Affairs will also be available on the call.  

The call can be accessed by dialing 1-866-356-4441 (domestic) or 1-617-597-5396

(international) five minutes prior to the start time and providing the access code 80227095.  The presentation will also be available by live webcast and can be accessed by visiting the Investors section of the Company's website at http://www.tengion.com or http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=218965&eventID=4169542.

A replay of the call will be available on the Tengion website approximately two hours after completion of the call and will be archived.

About TengionTengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications.  An initial clinical trial is ongoing for the Comp
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tengion Announces Leadership Transition
2. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
3. Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011
4. Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
5. Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011
6. Tengion Announces Pricing of $31.4 Million Private Placement
7. Tengion Addresses Recent Trading Activity in its Common Stock
8. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
9. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
10. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
11. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... world-leading provider of scientific, technical and medical information products ... study in Reproductive BioMedicine Online ... an abnormal chromosomal composition can be identified by the ... classifying the risk of genetic abnormality without a biopsy. ... a retrospective study, using their predictive model to assess ...
(Date:5/17/2013)... RESEARCH TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability , ... drought and insect pressures , Syngenta ... grand opening celebration today at the company’s RTP Innovation ... Crop Lab allows company researchers to simulate any agricultural ...
(Date:5/17/2013)... 2013  Cellular Biomedicine Group (OTCQB: CBMG) today ... the total projected enrollment required for its Phase ... efficacy of the medical technology haMPC (Human Adipose-derived ... To date the trial has had no Severe ... I open label clinical research trial for KOA, ...
(Date:5/17/2013)... 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce ... Switzerland -based Kenta Biotech to acquire ... (mAb) products, and technologies. This asset portfolio purchase ... of infections by common pathogens including drug resistant ... Pseudomonas aeruginosa , Acinetobacter baumannii and ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... Jan. 12 Synvista Therapeutics, Inc. (NYSE Alternext ... its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial ... measure the effect of alagebrium on exercise tolerance in patients ... completing enrollment of its BREAK ( B eginning a ...
... Ill. and SANTA ANA, Calif., Jan. 12 ,Abbott ( NYSE: ... EYE ) announced,today a definitive agreement for Abbott to acquire ... value of approximately $2.8 billion, inclusive,of estimated net debt at ... AMO,is a global leader in ophthalmic care, comprised of three ...
... Bavarian Nordic,owns several United States patents relating ... MVA-BN(R), which is the basis for its smallpox,vaccine, ... for delivering,recombinant vaccines. Bavarian Nordic has asserted three ... The claim in this case is that Oxford,BioMedica ...
Cached Biology Technology:Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7Bavarian Nordic's Case Against Oxford BioMedica 2
(Date:5/17/2013)... 2013) The AGA Research Foundation announced a new ... between the gut microbiota, one of today,s most exciting ... , The AGA Research Awards Panel selected Andrew T. ... Hospital and Harvard Medical School, Boston, as the 2013 ... will receive $25,000 of funding, commencing in July 2013, ...
(Date:5/17/2013)... May 17, 2013, Shenzhen, China---- Why Tibetan antelope ... Qinghai-Tibetan Plateau? In a collaborative research published in ... BGI, and other institutes provide evidence that some ... adaption to harsh highland environments. The data in ... specific genetic mechanisms and the biology of other ...
(Date:5/16/2013)... Bethesda, MD (May 17, 2013) Illustrating a ... the American Gastroenterological Association (AGA) Research Foundation ... Future Student Research Fellowship Award recipients. Supported by ... Kidney Diseases (NIDDK), this new award helps underrepresented ... digestive disease and nutrition research. , "By establishing ...
Breaking Biology News(10 mins):New gut microbiome research to explore red meat -- colorectal cancer pathway 2The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... found a group of mutations involved in T-cell acute ... in clinical use to treat other diseases, can eliminate ... next week in Nature Genetics and may ... The study was led by researcher Joo T. ...
... that predisposes people to acute myeloid leukemia and myelodysplasia ... the GATA2 gene. Among its several regulatory roles, ... transition of primitive blood-forming cells into white blood cells. ... families who, over generations, have had several relatives with ...
... & Dentistry at the University of Alberta have discovered that ... syndrome in some offspring that could lead to later health ... nuts and red wine, and has been shown to extend ... growing in the womb have an increased risk of developing ...
Cached Biology News:New mutations in leukemia: Researchers found mechanism that can help design future therapies 2New mutations in leukemia: Researchers found mechanism that can help design future therapies 3Gene defect that predisposes people to leukemia discovered 2Gene defect that predisposes people to leukemia discovered 3Powerful antioxidant resveratrol prevents metabolic syndrome in lab tests: U of A study 2
Direct ELISA Assay Diluent, 100 mL...
Direct ELISA Assay Diluent, 10 L...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
... routine agarose gel electrophoresis into an automated, ... This bufferless, pre-cast system is ideal for ... digests, and more. Fully automated, robot-compatible, and ... 96 system makes your high-throughput screening assignments ...
Biology Products: